Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
11.6.2021 08:58:09 CEST | ViroGates | Managers' transactions
COMPANY ANNOUNCEMENT - No. 16-2021 - 11 June 2021
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, yesterday evening received notice of the following transactions by persons discharging managerial responsibilities according to MAR art. 19. The transaction notification forms can be found in the attached document (pdf format).
Jørgen Thorball comments on the sale of shares: “I have high confidence in the prospects for ViroGates. I intend to remain a shareholder and sold the shares I have held for about 20 years to partly finance the subscription of shares based on the ViroGates 2015 warrant program and partly to pay the associated capital gains tax associated with the transaction. I do not intend to sell additional shares in 2021.”
The announcement can be found at https://www.virogates.com/investor/announcements
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.
ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
Disclosure regulation
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
Contacts
- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com